{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:57:09Z","timestamp":1790204229853,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00741-x","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:26:26Z","timestamp":1744032386000},"page":"865-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-245X","authenticated-orcid":false,"given":"James E.","family":"Galvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"20","key":"741_CR1","first-page":"3708","volume":"2024","author":"Alzheimer\u2019s Association","year":"2024","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dementia. 2024;2024(20):3708\u2013821.","journal-title":"Alzheimers Dementia"},{"key":"741_CR2","first-page":"773","volume":"32","author":"JA Silva-Rudberg","year":"2024","unstructured":"Silva-Rudberg JA, Carri\u00f3n CI, P\u00e9rez-Palmer N, Li J, Mehta SK, Diab NS, et al. Assessment of disparities in timely diagnosis and comprehensive workup of cognitive impairment between English and Spanish speakers. Am J Geriatr Psychiatry. 2024;32:773\u201386.","journal-title":"Am J Geriatr Psychiatry"},{"key":"741_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/gps.6158","volume":"39","author":"C Giebel","year":"2024","unstructured":"Giebel C, Silva-Ribeiro W, Watson J, Volkmer A, Chirico I, Diaz A, et al. A systematic review on the evidence of misdiagnosis in dementia and its impact on accessing dementia care. Int J Geriatr Psychiatry. 2024;39: e6158.","journal-title":"Int J Geriatr Psychiatry"},{"key":"741_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14283\/jpad.2023.131","volume":"11","author":"Y Liu","year":"2024","unstructured":"Liu Y, Jun H, Becker A, Wallick C, Mattke S. Detection of rates of mild cognitive impairment in primary care for the United States Medicare population. J Prev Alz Dis. 2024;11:7\u201312.","journal-title":"J Prev Alz Dis"},{"key":"741_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.960648","volume":"13","author":"M Casagrande","year":"2022","unstructured":"Casagrande M, Marselli G, Agostini F, Forte G, Favieri F, Guarino A. The complex burden of determining prevalence rates of mild cognitive impairment: a systematic review. Front Psychiatry. 2022;13: 960648.","journal-title":"Front Psychiatry"},{"key":"741_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3\u201345 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:1227\u201333.","journal-title":"Alzheimers Dement"},{"key":"741_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389:1096\u2013107.","journal-title":"N Engl J Med"},{"key":"741_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"741_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-240331","volume":"100","author":"JE Galvin","year":"2024","unstructured":"Galvin JE, Chang LC, Estes P, Harris HM, Fung E. Cognitive assessment with cognivue clarity: psychometric properties and normative ranges in a diverse population. J Alzheimers Dis. 2024;100:509\u201323.","journal-title":"J Alzheimers Dis"},{"key":"741_CR10","doi-asserted-by":"publisher","first-page":"24519","DOI":"10.1038\/s41598-024-75304-5","volume":"14","author":"JE Galvin","year":"2024","unstructured":"Galvin JE, Kleiman MJ, Estes PW, Harris HM, Fung E. Cognivue clarity characterizes mild cognitive impairment and Alzheimer\u2019s disease in biomarker confirmed cohorts in the Bio-Hermes study. Sci Rep. 2024;14:24519.","journal-title":"Sci Rep"},{"key":"741_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/13872877251314117","volume":"104","author":"JE Galvin","year":"2025","unstructured":"Galvin JE, Kleiman MJ, Estes PW, Harris HM, Fung E. Cognivue clarity characterizes amyloid status and preclinical Alzheimer\u2019s disease in biomarker confirmed cohorts in the Bio-Hermes study. J Alzheimer Dis. 2025;104:83\u201394.","journal-title":"J Alzheimer Dis"},{"key":"741_CR12","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/alz.13722","volume":"20","author":"RC Mohs","year":"2024","unstructured":"Mohs RC, Beauregard D, Dwyer J, Gaudioso J, Bork J, MaGee-Rogers T, et al. The bio-hermes study: biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:2752\u201365.","journal-title":"Alzheimers Dement"},{"key":"741_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"741_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"741_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"741_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4","volume":"40","author":"SJ Rosenberg","year":"1984","unstructured":"Rosenberg SJ, Ryan JJ, Prifitera A. Rey auditory-verbal learning test performance of patients with and without memory impairment. J Clin Psychol. 1984;40:785\u20137.","journal-title":"J Clin Psychol"},{"key":"741_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323\u20139.","journal-title":"J Gerontol"},{"key":"741_CR18","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvado G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"741_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","volume":"19","author":"Y Su","year":"2018","unstructured":"Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage Clin. 2018;19:406\u201316.","journal-title":"NeuroImage Clin"},{"key":"741_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"741_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"741_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","volume":"519","author":"KM Kirmess","year":"2021","unstructured":"Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, et al. The PrecivityAD\u2122 test: accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267\u201375.","journal-title":"Clin Chim Acta"},{"key":"741_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00234-5","volume":"10","author":"X Ding","year":"2021","unstructured":"Ding X, Zhang S, Jiang L, Wang L, Li T, Lei P. Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener. 2021;10:1\u201314.","journal-title":"Transl Neurodegener"},{"key":"741_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78:149\u201356.","journal-title":"JAMA Neurol"},{"key":"741_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14:1565\u201371.","journal-title":"Alzheimers Dement"},{"key":"741_CR26","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"741_CR27","unstructured":"Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, et al. \u201cLightGBM: a highly efficient gradient boosting decision tree.\u201d In: Proceedings of the 31st international conference on neural information processing systems. NIPS\u201917. Red Hook: Curran Associates Inc.; 2017. p. 3149\u201357."},{"key":"741_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-4302-5990-9_3","volume-title":"Efficient learning machines: theories, concepts, and applications for engineers and system designers","author":"M Awad","year":"2015","unstructured":"Awad M, Khanna R. Support vector machines for classification. In: Awad M, Khanna R, editors. Efficient learning machines: theories, concepts, and applications for engineers and system designers. New York: Apress Media; 2015. p. 39\u201366."},{"key":"741_CR29","doi-asserted-by":"crossref","unstructured":"Dietterich TG. Ensemble methods in machine learning. In: Multiple classifier systems: proceedings of the first international workshop on multiple classifier systems. 2000. p. 1\u201315.","DOI":"10.1007\/3-540-45014-9_1"},{"key":"741_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/ADR-230194","volume":"8","author":"T Chithiramohan","year":"2024","unstructured":"Chithiramohan T, Santhosh S, Threlfall G, Hull L, Mukaetova-Ladinska EB, Subramaniam H, et al. Culture-fair cognitive screening tools for assessment of cognitive impairment: a systematic review. J Alzheimers Dis Rep. 2024;8:289\u2013306.","journal-title":"J Alzheimers Dis Rep"},{"key":"741_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1212\/CPJ.0000000000000566","volume":"9","author":"JM Ranson","year":"2019","unstructured":"Ranson JM, Ku\u017ama E, Hamilton W, Muniz-Terrera G, Langa KM, Llewellyn DJ. Predictors of dementia misclassification when using brief cognitive assessments. Neurol Clin Pract. 2019;9:109\u201317.","journal-title":"Neurol Clin Pract"},{"key":"741_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jalz.2012.09.011","volume":"9","author":"CB Cordell","year":"2013","unstructured":"Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Medicare Detection of Cognitive Impairment Workgroup. Alzheimer\u2019s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9:141\u201350.","journal-title":"Alzheimers Dement"},{"key":"741_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13670-018-0236-2","volume":"7","author":"JE Galvin","year":"2018","unstructured":"Galvin JE. Using informant and performance screening methods to detect mild cognitive impairment and dementia. Curr Geriatr Rep. 2018;7:19\u201325.","journal-title":"Curr Geriatr Rep"},{"key":"741_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/alz.12773","volume":"19","author":"RJ Jutten","year":"2023","unstructured":"Jutten RJ, Papp KV, Hendrix S, Ellison N, Langbaum JB, Donohue MC, et al. Why a clinical trial is as good as its outcome measure: a framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:708\u201320.","journal-title":"Alzheimers Dement"},{"key":"741_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"741_CR36","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault J, Janelidze S, Benedet AL, Ashton NJ, Arranz Mart\u00ednez J, Gonzalez-Escalante A, et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat Aging. 2024;4:1529\u201337.","journal-title":"Nat Aging"},{"key":"741_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3233\/JAD-220891","volume":"91","author":"MJ Kleiman","year":"2023","unstructured":"Kleiman MJ, Ariko T, Galvin JE. Alzheimer\u2019s Disease Neuroimaging Initiative. Hierarchical two-stage cost-sensitive clinical decision support system for screening prodromal Alzheimer\u2019s disease and related dementias. J Alzheimers Dis. 2023;91:895\u2013909.","journal-title":"J Alzheimers Dis"},{"key":"741_CR38","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, Mattsson-Carlgren N, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5:fcad057.","journal-title":"Brain Commun"},{"key":"741_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363.","journal-title":"JAMA Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00741-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:57:59Z","timestamp":1747663079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00741-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James E. Galvin, MD, MPH is Chief Scientific Officer for Cognivue, Inc and receives consulting fees. Michael J. Kleiman, PhD received consulting fees from Cognivue, Inc to conduct statistical analyses. Heather M. Harris and Paul W. Estes are full-time employees of Cognivue, Inc. The authors take full responsibility for the data and have the right to publish all data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was reviewed and approved by Advarra, a central institutional review board (Reference Number Pro00046018), and was conducted in accordance with the Helsinki Declaration of 1964. The study was registered on ClinicalTrials.gov (NCT04733989).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}